丽珠医药：莱康奇塔单抗注射液上市许可申请获国家药品监督管理局受理

Core Viewpoint - Lijun Pharmaceutical's subsidiary, Zhuhai Lijun Monoclonal Antibody Biotechnology Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for the registration application of the monoclonal antibody injection, Laikangqita, developed in collaboration with Beijing Xinkanghe Biological Pharmaceutical Technology Co., Ltd. [1] Group 1 - The acceptance notice is identified with the registration number CXSS2500144 [1] - The drug registration application is for domestic production [1] - The collaboration involves a partnership with Beijing Xinkanghe [1]